Drug Trial Radar · NCT07169578
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,101
Actual
Start
Sep 17, 2025
Primary completion
Feb 16, 2028
Study completion Feb 16, 2028
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Sep 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).
Conditions
- Alzheimers Disease
Interventions
TrontinemabDrug
Participants will receive IV trontinemab.
PlaceboOther
Participants will receive IV placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 72 in Clinical Dementia Rating, Sum of Boxes (CDR-SB)Time frame: Baseline - Week 72
Locations
142 sites in 13 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Banner Sun Health Research Institute
Sun City, Arizona
Irvine Center for Clinical Research
Irvine, California
Inglewood Clinicals
Los Angeles, California
UCSF - Memory and Aging Center
San Francisco, California
Syrentis Clinical Research
Santa Ana, California
K2 Medical Research - The Villages
Lady Lake, Florida
K2 Medical Research, LLC
Maitland, Florida
Renstar Medical Research
Ocala, Florida
Axiom Brain Health LLC
Tampa, Florida
Charter Research - Lady Lake/The Villages
The Villages, Florida
Alzheimer?s Research and Treatment Center
Wellington, Florida
Conquest Research, LLC
Winter Park, Florida
Alzheimer's Research and Treatment Center - Columbus
Columbus, Georgia
Accel Research Sites-NeuroStudies
Decatur, Georgia
Hawaii Pacific Neuroscience
Honolulu, Hawaii
RE:Cognition (Chicago)
Chicago, Illinois
Tandem Clinical Research, LLC
Marrero, Louisiana
Brigham and Womens Hospital
Boston, Massachusetts
Boston Center for Memory
Newton, Massachusetts
Washington University School of Medicine
St Louis, Missouri
The Cognitive and Research Center of New Jersey
Ridgewood, New Jersey
Basil Clinical
Laurelton, New York
Weill Cornell Medical College
New York, New York
Adams Clinical Harlem
New York, New York
Adams Clinical Bronx
The Bronx, New York
Triad Clinical Trials
Greensboro, North Carolina
Ohio State University
Columbus, Ohio
Butler Hospital
Providence, Rhode Island
Genesis Neuroscience Clinic
Knoxville, Tennessee
K2 Medical Research - Nashville
Nashville, Tennessee
Kerwin Research Center, LLC
Dallas, Texas
South Texas Research Institute - Edinburg
Edinburg, Texas
Re:Cognition Health - Houston
Houston, Texas
National Clinical Research Inc.-Richmond
Richmond, Virginia
Hospital Italiano
CABA, Argentina
Hospital das Clinicas - UFMG
Belo Horizonte, Minas Gerais, Brazil
Hospital Moinhos de Vento
Porto Alegre, Rio Grande do Sul, Brazil
Centro de Pesquisas Clinicas - CPCLIN
São Paulo, São Paulo, Brazil
Alpha Recherche Clinique
Québec, Canada
Showing 40 of 142 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.